Answers are grounded in this paper and cite their sources.
The COVID-19 pandemic and related interventions disrupted the typical seasonal patterns of bronchiolitis, leading to a significant decline in hospitalizations and disease severity. However, during the 2022–2023 winter season, bronchiolitis cases surged, with both the number of hospitalizations and disease severity exceeding pre-pandemic levels. Given these fluctuations, we considered it crucial to monitor the burden of bronchiolitis, particularly in light of the upcoming universal respiratory syncytial virus prophylactic antibody coverage in Italy. We retrospectively evaluated bronchiolitis-related hospitalizations and disease severity in infants (< 1 year) during winter seasons (September 1st to March 31st) across seven Italian hospitals from 2018 to 2019 through 2023–2024. A total of 833 infants were hospitalized for bronchiolitis during the 2023–2024 winter season across the seven participating hospitals, decreasing from 1102 in 2022–2023 and representing the first decline since the 2021–2022 season. The proportion of tested infants who were RSV-positive did not differ significantly between 2023 and 2024 and 2022–2023 (82% vs. 79%); the fall in RSV-positive admissions therefore mirrored the overall decline in hospitalization numbers rather than a reduction in RSV positivity. Compared with 2022–2023, a significantly smaller proportion of infants required oxygen supplementation, high-flow nasal cannula, or intensive care unit admission, although the duration of respiratory support among infants who required it did not decrease and was, if anything, marginally longer. Hospital length of stay did not differ significantly between the two seasons. Several indicators - including RSV positivity and the proportion of infants requiring oxygen or high-flow nasal cannula - remained significantly higher than pooled pre-pandemic (2018–2020) values, while the proportion requiring intensive care unit admission had returned to a level statistically similar to the pre-pandemic period. Our findings indicate a partial return toward pre-pandemic bronchiolitis epidemiology during the 2023–2024 winter season, with fewer infants requiring escalated respiratory support than in 2022–2023, although several indicators remained above pre-pandemic levels. Continued monitoring remains important, particularly in anticipation of the upcoming respiratory syncytial virus prophylactic antibody program in Italy.
No takes yet. Share an insight, caveat, or question.
Ghirardo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: